Fixed-duration ibrutinib-venetoclax with MRD-guided ibrutinib-obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial.

Arnon P Kater, Sabina Kersting, Julie M Dubois, Bronno van der Holt, Caspar da Cunha-Bang, Doreen Te Raa, Cecile Idink, Fransien de Boer, Jolanda Droogendijk, Koen de Heer, Leonie van der Burg, Marten R Nijziel, Lidwien Tick, Henriette Levenga, Matthijs Silbermann